TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA)

Every figure this model derived for TEVA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 550,000,000 PaymentsToAcquireProductiveAssets 2026-06-30
cash 3,693,000,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 13,760,000,000 AssetsCurrent 2026-06-30
current liabilities 15,646,000,000 LiabilitiesCurrent 2026-06-30
equity 7,753,000,000 StockholdersEquity 2026-06-30
interest expense 916,000,000 InterestExpense 2025-12-31
ocf 1,898,000,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 17,315,000,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 168,000,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TEVA on one particular measure came for.

RatioValue
cash operating margin15.94
current ratio0.88
current ratio reported0.88
dilution pct2.83
ebit yoy79.31
fcf margin7.79
growth cv6.08
interest cover1.75
net debt ebitda0.31
operating margin9.26
owner earnings margin6.81
revenue growth4.13
revenue growth per share1.26
roic14.79
rule of 4013.39
sbc pct revenue0.97

What to be careful about

What this model itself distrusts about TEVA's figures. Written by the derivation as it ran, not added afterwards.